CADTH Health Technology Review

Reconsolidation and Consolidation Therapies for the Treatment and Prevention of Post-Traumatic Stress Disorder
Table of Contents

Abbreviations .......................................................................................................................................................................... 6
Key Messages ................................................................................................................................................................................ ..7
Context and Policy Issues ............................................................................................................................................................. 7
Research Questions ........................................................................................................................................................................... 9
Methods ........................................................................................................................................................................................... 9
  Literature Search Methods ........................................................................................................................................................... 9
  Selection Criteria and Methods .................................................................................................................................................... 9
  Exclusion Criteria .......................................................................................................................................................................... 10
  Critical Appraisal of Individual Studies ...................................................................................................................................... 10
Summary of Evidence ....................................................................................................................................................................... 10
  Quantity of Research Available .................................................................................................................................................... 10
  Summary of Study Characteristics .............................................................................................................................................. 11
  Summary of Critical Appraisal .................................................................................................................................................... 13
  Summary of Findings ...................................................................................................................................................................... 15
Limitations .......................................................................................................................................................................................... 18
Conclusions and Implications for Decision- or Policy-Making ................................................................................................................. 19
References .......................................................................................................................................................................................... 21
Appendix 1: Selection of Included Studies ........................................................................................................................................ 23
Appendix 2: Characteristics of Included Publications .......................................................................................................................... 24
Appendix 3: Critical Appraisal of Included Publications ................................................................................................................................ 27
Appendix 4: Main Study Findings ...................................................................................................................................................... 30
Appendix 5: Overlap Between Included Systematic Reviews .................................................................................................................. 42
Appendix 6: References of Potential Interest ....................................................................................................................................... 45
List of Tables

Table 1: Selection Criteria ............................................................................................................. 10
Table 2: Characteristics of Included Systematic Reviews and Meta-Analyses ........................................ 24
Table 3: Strengths and Limitations of Systematic Reviews and Meta-Analyses Using AMSTAR 220 .............. 27
Table 4: Summary of Findings by Outcome — PTSD, Depression, and Anxiety (Reconsolidation Therapy) .......... 30
Table 5: Summary of Findings by Outcome — Treatment Dropout and Adherence (Reconsolidation Therapy) ..... 34
Table 6: Summary of Findings by Outcome — Additional Outcomes (Reconsolidation Therapy) .................. 36
Table 7: Summary of Findings by Outcome — PTSD (Consolidation Therapy) ........................................ 37
Table 8: Summary of Findings by Outcome — Treatment Dropout (Consolidation Therapy) .......................... 40
Table 9: Summary of Findings by Outcome — Additional Outcomes (Consolidation Therapy) ...................... 41
Table 10: Overlap in Relevant Primary Studies Between Included Systematic Reviews .................................... 42
List of Figures

Figure 1: Selection of Included Studies .............................................................. 23
Abbreviations

PTSD  post-traumatic stress disorder
RCT  randomized controlled trial
Key Messages

- The evidence about the clinical effectiveness of reconsolidation and consolidation therapies for the treatment and prevention of post-traumatic stress disorder (PTSD) is uncertain because these therapies include a wide range of interventions and the study results varied widely.
- The results from 1 systematic review suggest there were significantly greater improvements in PTSD severity in patients treated with reconsolidation therapy versus control. However, 3 other systematic reviews reported conflicting findings with some reconsolidation therapies indicating significant improvements in PTSD symptoms or severity versus control, whereas other reconsolidation therapies had no significantly different outcomes than the control groups.
- There was limited evidence suggesting that multi-modular motion-assisted memory desensitization and reprocessing therapy reduced PTSD symptoms in veterans with treatment-resistant and combat-related PTSD; however, the significance of these results was not reported.
- There was limited evidence suggesting a significant difference in PTSD incidence in favour of adults exposed to trauma treated with hydrocortisone versus control. There were no significant differences in PTSD incidence between adults exposed to trauma treated with any 1 of propranolol, omega-3 fatty acids, gabapentin, or paroxetine versus placebo.

Context and Policy Issues

Post-traumatic stress disorder (PTSD) is a psychiatric disorder that can develop in individuals following exposure to a traumatic event. Symptoms of PTSD include intrusive and distressing memories or dreams, dissociative reactions, and psychological or physiologic distress related to the traumatic event. The person with PTSD must have been exposed to actual or threatened death, serious injury, or sexual violation. The person may have directly experienced or witnessed the traumatic event, learned that the event occurred to a close family member or friend, or experienced repeated exposure to details of the trauma. Symptoms must be present for at least 1 month for a diagnosis of PTSD. PTSD is associated with a variety of comorbidities, including depression, substance use disorders, chronic pain, and sleep problems. Acute stress disorder has similar symptoms to PTSD; however, it is diagnosed between 3 days and 1 month after the traumatic event. Additionally, the risk of suicide attempts is 2- to 3-fold higher in those with PTSD. The lifetime prevalence of PTSD in Canada is estimated to be 9.2% and is approximately twice as high in women as in men.

Treatment for PTSD includes both pharmacotherapy and psychotherapy. Some of the psychotherapies that have been used to treat PTSD include cognitive behavioural therapy, cognitive processing therapy, and prolonged exposure therapy. Some of the pharmacological therapies that have been used in the treatment of PTSD include selective serotonin reuptake inhibitors (e.g., fluoxetine, paroxetine, sertraline), serotonin and noradrenaline reuptake inhibitors (e.g., venlafaxine, duloxetine), and atypical antipsychotic drugs (e.g., risperidone, olanzapine). Reconsolidation and consolidation therapies are emerging as a potential treatment and preventive options, respectively, for PTSD.

Memories are thought to be initially modifiable when they are first acquired and then solidify through the synthesis of new proteins in a process known as consolidation.
consolidation therapy aims to disrupt traumatic memories before the consolidation process takes place. Consolidation therapy uses pharmacological drugs such as propranolol or behavioural approaches administered shortly after a traumatic event to prevent the development of acute stress disorder or PTSD. An example of a behavioural approach that can be used in consolidation therapy is competing tasks, such as using a video game with high visuospatial demands aimed to interfere with the consolidation of traumatic memories.

The traditional theory in the memory field was that memories could not be changed once the consolidation process had occurred. This theory was displaced after literature was published that showed that after memory retrieval, previously consolidated memories become destabilized and require protein synthesis for long-term storage in a process termed reconsolidation. A range of research into reconsolidation was conducted due to its potential as a therapeutic target for various disorders, including PTSD. Reconsolidation was first studied in animals; however, the interventions used to disrupt reconsolidation (e.g., hypothermia, pharmacological drugs with serious adverse effects or toxicity) were not translatable to humans. Later studies in animal models found that reconsolidation could be targeted through the use of propranolol. Propranolol was then studied in humans and has been found to help with diminishing emotions associated with fear memories.

Reconsolidation therapy involves the combination of a memory reactivation therapy with a pharmacological drug or brain stimulation treatment. Pharmacological drugs used in reconsolidation therapy can include propranolol, D-cycloserine, oxytocin, and hydrocortisone. Brain stimulation treatments can include transcranial magnetic stimulation and transcranial electrical current stimulation. One example of a memory reactivation therapy that can be used in reconsolidation therapy is prolonged exposure therapy. During prolonged exposure therapy, participants work with a therapist and are exposed to stimuli that evoke fear and remind them of their past trauma with the goal of increasing their comfort and reducing their fear.

Several brain regions, including the amygdala, prefrontal cortex, hypothalamus, and hippocampus, are involved in PTSD. The amygdala is regulated by the prefrontal cortex and has a critical role in fear and anxiety, and modulates memory consolidation. Hyperactivity of the amygdala in patients with PTSD leads to impairment of the fear extinction system. Additionally, the noradrenergic system (a system of neurons responsible for the neurotransmitter norepinephrine) plays a role in the regulation of some PTSD symptoms, including nightmares, sleep dysregulation, and hyperarousal. The consolidation of fear memories is associated with the beta-adrenergic receptors and norepinephrine system because the binding of norepinephrine to these receptors causes memory consolidation through promotion of the synthesis of certain proteins. Further, studies have suggested that glucocorticoids enhance fear extinction and reduce retrieval of aversive memories, and that fear extinction is linked to N-methyl-d-aspartate receptor function in the amygdala.

A wide range of pharmacological drugs may be used in consolidation and reconsolidation therapy. Due to the involvement of the noradrenergic system and beta-adrenergic receptors in PTSD, as well as the consolidation of fear memories, adrenoreceptor blockers (such as yohimbine) and beta-adrenergic blockers (such as propranolol) are potential therapeutic options. Additionally, glucocorticoids (e.g., dexamethasone and hydrocortisone) and N-methyl-d-aspartate receptor agonists (e.g., D-cycloserine) may have a role in reconsolidation and consolidation therapy. Lastly, intranasal oxytocin has been shown to enhance fear extinction in healthy individuals and reduce amygdala hyperactivity in patients with PTSD.
Nonpharmacological options used in reconsolidation therapy can include brain stimulation treatments, which target brain regions such as the prefrontal cortex, amygdala, or hippocampus and may reduce PTSD symptoms and be used in reconsolidation therapy. Fear extinction may be enhanced by transcranial magnetic stimulation and fear memory consolidation may be disrupted by transcranial direct current stimulation.

The aim of the current report is to summarize the evidence regarding the clinical effectiveness of reconsolidation therapy for the treatment of adults with PTSD and consolidation therapy for the prevention of acute stress disorder or PTSD in adults who have experienced trauma.

Research Questions
1. What is clinical effectiveness of reconsolidation therapy versus placebo or no treatment for adults with PTSD?
2. What is clinical effectiveness of reconsolidation therapy versus alternative interventions for adults with PTSD?
3. What is clinical effectiveness of consolidation therapy versus placebo or no treatment placebo for the prevention of PTSD or acute stress disorder in adults who have experienced trauma?
4. What is clinical effectiveness of consolidation therapy versus alternative interventions for the prevention of PTSD or acute stress disorder in adults who have experienced trauma?

Methods

Literature Search Methods
A limited literature search was conducted by an information specialist on key resources including MEDLINE, PsycInfo, the Cochrane Database of Systematic Reviews, the international HTA database, the websites of Canadian and major international health technology agencies, as well as a focused internet search. The search strategy comprised both controlled vocabulary, such as the National Library of Medicine’s MeSH (Medical Subject Headings), and keywords. The main search concepts were post-traumatic stress disorder and reconsolidation/consolidation therapy. A secondary search was conducted with the concepts post-traumatic stress disorder and pharmacotherapies. CADTH-developed search filters were applied to limit retrieval for this secondary search to health technology assessments, systematic reviews, meta-analyses, network meta-analyses, or any types of clinical trials or observational studies. The searches were completed on March 30, 2022, and limited to English-language documents published since January 1, 2017.

Selection Criteria and Methods
One reviewer screened citations and selected studies. In the first level of screening, titles and abstracts were reviewed and potentially relevant articles were retrieved and assessed for
inclusion. The final selection of full-text articles was based on the inclusion criteria presented in Table 1.

**Exclusion Criteria**

Articles were excluded if they did not meet the selection criteria outlined in Table 1, they were duplicate publications, or were published before 2017. Systematic reviews in which all relevant studies were captured in other, more recent or more comprehensive systematic reviews were excluded.31219

**Critical Appraisal of Individual Studies**

The included systematic reviews were critically appraised by 1 reviewer using A MeaSurement Tool to Assess systematic Reviews 2 (AMSTAR 2).20 Summary scores were not calculated for the included studies; rather, the strengths and limitations of each included publication were described narratively.

**Summary of Evidence**

**Quantity of Research Available**

A total of 880 citations were identified in the literature search. Following screening of titles and abstracts, 825 citations were excluded and 55 potentially relevant reports from the electronic search were retrieved for full-text review. Two potentially relevant publications were retrieved from the grey literature search for full-text review. Of these potentially relevant articles, 51 publications were excluded for various reasons, and 6 systematic reviews met the inclusion criteria and were included in this report. Appendix 1 presents the PRISMA21 flow chart of the study selection.

**Table 1: Selection Criteria**

<table>
<thead>
<tr>
<th>Criteria</th>
<th>Description</th>
</tr>
</thead>
</table>
| Population    | Q1 and Q2: Adults (aged 18 years or older) with PTSD  
                 Q3 and Q4: Adults (aged 18 years or older) who have experienced trauma                                                                  |
| Intervention  | Q1 and Q2: Reconsolidation therapy  
                 Q3 and Q4: Consolidation therapy                                                                                                         |
| Comparator    | Q1 to Q3: Placebo or no treatment  
                 Q2 to Q4: Alternative interventions (e.g., psychotherapy, such as cognitive behavioural therapy; pharmacotherapy)                       |
| Outcomes      | Q1 and Q2: Clinical effectiveness (e.g., symptom severity [e.g., PTSD symptoms, depressive symptoms], quality of life, safety [e.g., rate of adverse events, side effects])  
                 Q3 and Q4: Clinical effectiveness (e.g., incidence of PTSD, incidence of acute stress disorder, severity of PTSD, quality of life, safety [e.g., rate of adverse, side effects]) |
| Study designs | Health technology assessments, systematic reviews                                                                                           |

PTSD = post-traumatic stress disorder.
Additional references of potential interest are provided in Appendix 6.

Summary of Study Characteristics

In total, 6 systematic reviews were included in this report comprising 2 with meta-analyses,\textsuperscript{22,23} 1 with a network meta-analysis,\textsuperscript{24} and 3 others without pooled statistical analysis to estimate an overall combined treatment effect.\textsuperscript{25-27} There were 4 systematic reviews\textsuperscript{22,24,26,27} that included primary studies evaluating reconsolidation therapy, and 2 systematic reviews\textsuperscript{22,23} that included primary studies evaluating consolidation therapy.

All of the included systematic reviews had inclusion criteria that are broader than the present report. Specifically, 5 of the systematic reviews\textsuperscript{22,24-27} evaluated a range of interventions for PTSD other than consolidation or reconsolidation therapy. The systematic review by Baas et al. (2020)\textsuperscript{25} included studies evaluating any intervention for the treatment of PTSD in pregnant women with PTSD or exposure to trauma; however, none of the included studies evaluated reconsolidation or consolidation therapy for PTSD. Additionally, 1 of the systematic reviews\textsuperscript{23} included studies in pediatric participants in addition to studies in adult participants. Only the characteristics and results of the subset of relevant studies will be described in this report.

Additional details regarding the characteristics of the included publications are provided in Appendix 2.

Study Design

The systematic review and meta-analysis by Bertolini et al. (2022)\textsuperscript{22} included 13 randomized controlled trials (RCTs), 12 of which are relevant to the present report. Literature searches were conducted up to November 13, 2020, and no restrictions were imposed based on date of publication.\textsuperscript{22} The systematic review and meta-analysis by Astill Wright et al. (2021)\textsuperscript{23} included 25 RCTs, 24 of which are relevant to the present report. Literature searches were conducted up to March 20, 2020, and no restrictions were imposed based on date of publication.\textsuperscript{23} The systematic review by Baas et al. (2020)\textsuperscript{25} included 3 RCTs and 10 non-randomized studies, none of which are relevant to the present report. The search time frame was 1980 to June 2019.\textsuperscript{25} The systematic review by Knaust et al. (2020)\textsuperscript{26} included 18 studies in total, of which 6 RCTs, 1 single-arm before-after study, and 3 case studies are relevant to the present report. The search time frame was January 2013 to July 2020.\textsuperscript{26} The systematic review by Metcalf et al. (2020)\textsuperscript{27} included 34 RCTs, 12 of which are relevant to the present report. Literature searches were conducted up to December 21, 2018, and no restrictions were imposed based on date of publication.\textsuperscript{27} The systematic review and network meta-analysis by Merz et al. (2019)\textsuperscript{24} included 12 RCTs, 6 of which are relevant to the present report. The search time frame was January 1, 1980, to February 28, 2018.\textsuperscript{24} Results of the network meta-analysis are not presented in the present report due to overlap of relevant primary studies with other included systematic reviews and the inclusion of primary studies that are not relevant to this report in the network meta-analysis.

Four of the included systematic reviews\textsuperscript{22,24,27} had overlap in their included primary studies. Twelve primary studies were included in more than 1 systematic review. A citation matrix depicting the overlap between the included systematic reviews is provided in Appendix 5. Only primary studies that provide direct evidence that is relevant to this report were included in the overlap table.
Country of Origin
The included systematic reviews were conducted by authors in Italy,22 the UK,23 the Netherlands,25 Germany,26 Australia,27 and Switzerland.24

The relevant primary studies included in the systematic reviews by Bertolini et al. (2022),22 Astill Wright et al. (2021),23 and Knaust et al. (2020)26 were conducted in Canada, the US, Germany, Israel, the Netherlands, Japan, Romania, Brazil, Switzerland, and the UK. The countries where the relevant primary studies were conducted in the systematic reviews by Metcalf et al. (2020)27 and Merz et al. (2020)24 were not reported.

Patient Population
Two of the systematic reviews22,23 included studies of adults exposed to a traumatic event. In the systematic review by Bertolini et al. (2022),22 participants had to be exposed to the traumatic event within 3 months of receiving the intervention. The systematic review by Bertolini et al. (2022)22 excluded studies of participants who were symptomatic at baseline. In the systematic review by Astill Wright et al. (2021),23 participants were exposed to the traumatic event within 72 hours of receiving the intervention. The other 3 systematic reviews24,26,27 included studies of adults diagnosed with PTSD. The 5 included systematic reviews22,24,26,27 encompassed studies of participants that were exposed to a range of traumatic events, including assault, injury, motor vehicle accident, cardiac surgery, septic shock, Caesarean section, and combat-related events.

Interventions and Comparators
The systematic review by Bertolini et al. (2022)22 included studies of any pharmacological intervention administered with the intention to prevent the onset of PTSD or PTSD symptoms within 3 months of trauma. The consolidation interventions evaluated in the relevant studies include dexamethasone, hydrocortisone, propranolol, gabapentin, omega-3 fatty acids, paroxetine, and 5-hydroxytryptophan.22 The eligible comparators were placebo or any active pharmacological drug.

The systematic review by Astill Wright et al. (2021)23 included any consolidation- or reconsolidation-based prevention or treatment intervention. For reconsolidation, the interventions evaluated in the relevant studies include propranolol with memory reactivation, mifepristone with memory reactivation, mifepristone and D-cycloserine with memory reactivation, hydrocortisone with memory reactivation, sirolimus with memory reactivation, electroconvulsive therapy with memory reactivation, and reconsolidation of traumatic memories.23 The consolidation interventions evaluated in the relevant studies include hydrocortisone, dexamethasone, propranolol, oxytocin, a virtual reality pain task, a cognitive task memory interference procedure, and a cognitive task memory interference procedure with memory reactivation.23 The eligible comparators were placebo, pharmacological, or psychosocial interventions.

The systematic review by Knaust et al. (2020)26 included studies of any virtual trauma intervention that used immersive technology with the goal to reduce PTSD symptoms. Immersive technology was defined as technology that delivers an inclusive, extensive, surrounding, and vivid illusion of reality.25 The reconsolidation interventions evaluated in the relevant studies include multi-modal motion-assisted memory desensitization and reconsolidation, virtual reality exposure therapy with D-cycloserine, virtual reality exposure therapy with dexamethasone, virtual reality exposure therapy with alprazolam, and
virtual reality exposure therapy with transcranial direct current stimulation. The eligible comparators were not specified.

The systematic review by Metcalf et al. (2020) included studies of any first-line PTSD treatment in combination with an augmentation intervention. Augmentation interventions were defined as any psychological, nonpsychological, or pharmacological intervention, delivered before, along with, or after a first-line PTSD treatment. The reconsolidation interventions evaluated in the relevant studies include prolonged exposure therapy in combination with 1 of the following: repetitive transcranial magnetic stimulation, D-cycloserine, oxytocin, yohimbine, hydrocortisone, methylene blue, paroxetine, or sertraline. The eligible comparators were first-line PTSD treatments alone.

The systematic review by Merz et al. (2019) included studies of any psychotherapeutic treatments, pharmacological treatments, or combinations of both. The reconsolidation interventions evaluated in the relevant studies include prolonged exposure therapy with sertraline or paroxetine, and exposure therapy with fluoxetine. The eligible comparators were any active psychotherapeutic or pharmacological PTSD treatment.

Outcomes

The systematic reviews used a range of scales to assess PTSD severity. These include the Clinician-Administered PTSD Scale, the PTSD Checklist, Post-Traumatic Stress Symptom 10-Question Inventory questionnaire, the Post-traumatic Stress Diagnostic Scale, the Post-traumatic Symptom Scale, Mini-International Neuropsychiatric Interview, and Davidson Trauma Scale.

The systematic reviews by Bertolini et al. (2022) and Astill Wright et al. (2021) assessed PTSD incidence using a range of tools, including the Clinician-Administered PTSD Scale, Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (known as DSM-IV)—based interviews, Comprehensive International Diagnostic Interview PTSD, the Post-traumatic Symptom Scale, Post-traumatic Stress Symptom 10-Question Inventory questionnaire, the Self-Rating Inventory for PTSD, the PTSD Checklist, and the revised Impact of Events Scale.

The systematic review by Astill Wright et al. (2021) assessed the severity of symptoms of re-experiencing traumatic memories using re-experiencing subscales and intrusive memories that were reported using a paper diary.

In the systematic review by Bertolini et al. (2022), quality of life was assessed using the 36-Item Short-Form Health Survey and depression was assessed using the Center for Epidemiologic Studies Depression scale, the Quick Inventory of Depressive Symptomatology, and the Montgomery-Asberg Depression Rating Scale. The systematic review by Metcalf et al. (2020) did not report the scales used to assess depression, anxiety, and quality of life.

Summary of Critical Appraisal

Additional details regarding the strengths and limitations of the included publications are provided in Appendix 3.

Since the systematic review by Baas et al. (2020) did not include any relevant primary studies, only the sections relevant to this report (e.g., protocol, search strategy) were critically appraised. Additionally, the network meta-analysis conducted as part of the Merz et al.
systematic review was not critically appraised given that it included results from studies that are not relevant to the present report.

The study eligibility criteria were clearly defined for all of the included systematic reviews. However, eligible comparators were not specified in the systematic reviews by Baas et al. (2020) and Knaust et al. (2020). The review methods were established before the conduct of the review for 4 of the systematic reviews. The protocol of the Bertolini et al. (2022) systematic review was published and the other 3 systematic reviews registered their protocols. The authors of the Knaust et al. (2020) review stated that the inclusion criteria were established a priori; however, they do not state whether other methods (e.g., search strategy, research questions) were established before conducting the review. The authors of the Metcalf et al. (2020) systematic review do not state whether any of the review methods were established before conducting the review. This has the potential to introduce bias if the review methods were adjusted after the review had begun.

All of the searches were conducted in multiple databases and the key search terms used were provided. Five of the systematic reviews also searched trial registries. The authors of the Knaust et al. (2020) review do not state whether they searched trial registries. Additionally, the authors of the Knaust et al. (2020) and Metcalf et al. (2020) reviews do not state whether they handsearched the reference lists of the included articles to identify additional literature. Providing details of these elements of the search strategy increases its reproducibility. Study selection was performed by 2 independent reviewers in 3 of the systematic reviews. In 2 of the systematic reviews, full-text screening was performed in duplicate; however, abstract screening was done by a single reviewer in the review by Baas et al. (2020) and the authors of the Merz et al. (2019) review did not state whether abstract screening was performed in duplicate. The authors of the Metcalf et al. (2020) review did not state whether study selection was performed in duplicate. Performing study selection in duplicate helps reduce the risk of bias in study selection. A list of excluded studies with reasons for exclusion was provided in the systematic review by Bertolini et al. (2022). The other 5 systematic reviews did not provide lists of the excluded studies; however, they did provide reasons for exclusion in flow charts of study selection. Unjustified exclusion of studies could bias the results of the review.

Data extraction was performed in duplicate in 3 of the systematic reviews. In the systematic review by Metcalf et al. (2020), 1 reviewer extracted data and another reviewer checked the data. The authors of the Knaust et al. (2020) systematic review do not state whether data extraction was performed in duplicate. Performing data extraction in duplicate increases the completeness and accuracy of data capture. The included primary studies were described in detail in the systematic review by Bertolini et al. (2022). In the other 4 systematic reviews, some details of the included primary studies were not reported. The time frame for follow-up and countries for the included primary studies were not specified in the systematic reviews by Metcalf et al. (2020) and Merz et al. (2019). The risk of bias in included primary studies was assessed using a satisfactory technique in 4 of the systematic reviews. In 3 of these systematic reviews, the risk of bias assessment was performed independently by 2 reviewers. Risk of bias in the included primary studies was not assessed in the systematic review by Knaust et al. (2020). Appropriate methods for the statistical combination of results were used in the meta-analysis by Bertolini et al. (2022). A random-effects model was used for the meta-analysis due to clinical heterogeneity among the included primary studies. Only results from studies assessing the same intervention were combined in meta-analysis. Subgroup analyses excluding studies at high risk of bias from the meta-analysis were pre-planned; however, they could not be carried out due to a
lack of data. Additionally, publication bias could not be assessed through funnel plots due to the low number of studies per comparison. In the systematic review by Astill Wright et al. (2021) statistical heterogeneity was assessed and the choice of a fixed- or random-effects model for the meta-analysis followed from this assessment. However, due to the inclusion of heterogeneous interventions, a random-effects model may have been more appropriate for all analyses. Further, it may not have been appropriate to combine the results from studies that assessed a wide range of heterogeneous interventions into a single pooled estimate. However, heterogeneity was assessed through several sensitivity analyses of subgroups of various interventions. Sensitivity analyses to assess the impact of risk of bias in individual studies on results of the meta-analysis were not performed and the authors do not state whether they assessed publication bias. The funding sources for the review were reported and potential conflicts of interest were disclosed in 3 of the systematic reviews. The funding source for the systematic review by Metcalf et al. (2020) was reported; however, the authors did not state whether they had any potential conflicts of interest. Potential conflicts of interest were disclosed by the authors of the Merz et al. (2019) systematic review; however, the funding source for the review was not reported.

Summary of Findings

The overall findings of the included studies are presented in the following text. Detailed summaries of the main findings are provided in Appendix 4. There was some overlap in the primary studies that were included in the systematic reviews; the pooled estimates from separate reviews thus contain some of the same data. A citation matrix illustrating the degree of overlap is presented in Appendix 5. When possible, data from relevant primary studies were presented only once.

Clinical Effectiveness of Reconsolidation Therapy

PTSD Severity

The meta-analysis conducted by Astill Wright et al. (2021) pooled results from studies that evaluated various reconsolidation interventions versus control groups. The meta-analysis suggested there were statistically significant differences in PTSD severity and re-experiencing severity at 1 to 4 weeks in favour of all pharmacological, electroconvulsive therapy, and psychological reconsolidation interventions (pooled result of a range of reconsolidation therapies) versus control. There were statistically significant differences in PTSD severity and re-experiencing severity at 2 weeks in favour of reconsolidation of traumatic memories versus control. There was no significant difference in PTSD severity at 1 to 4 weeks for all pharmacological and electroconvulsive therapy reconsolidation interventions versus control. There was no significant difference in PTSD severity at 1 week for propranolol with memory reactivation versus control.

The systematic reviews by Knaust et al. (2020), Metcalf et al. (2020), and Merz et al. (2019) reported results from relevant primary studies individually. A wide range of reconsolidation therapies were evaluated. The results of some of the relevant primary studies suggested there were significant differences in PTSD symptoms or severity in favour of reconsolidation therapy versus control whereas results from other studies suggested there were no significant differences between treatment groups.

The systematic review by Knaust et al. (2020) reported that virtual reality exposure therapy with D-cycloserine was superior to virtual reality exposure therapy with placebo for PTSD severity (1 RCT). However, results from a different relevant RCT included in the systematic
review suggested there were no significant difference in PTSD severity measured post-treatment between virtual reality exposure therapy with D-cycloserine and virtual reality exposure therapy with placebo.26 The systematic review reported a significant difference in PTSD severity measured at post treatment that favoured virtual reality exposure therapy with placebo versus virtual reality exposure therapy with alprazolam (1 RCT).26 Multi-modular motion-assisted memory desensitization and reconsolidation therapy reduced PTSD symptoms in veterans with treatment-resistant and combat-related PTSD (2 RCTs); however, the significance of these results versus control groups was not reported.26 The systematic review also reported modest therapy gains (1 single-arm before-after study) and positive treatment results (3 case studies) for patients with treatment-resistant and combat-related PTSD treated with multi-modular motion-assisted memory desensitization and reconsolidation therapy.26

The systematic review by Metcalf et al. (2020)27 reported no significant difference in PTSD symptoms for prolonged exposure with intranasal oxytocin (1 RCT), prolonged exposure with yohimbine (1 RCT), imaginal exposure with methylene blue (1 RCT), or prolonged exposure with sertraline (2 RCTs) versus control groups. The systematic review reported mixed results for prolonged exposure with D-cycloserine.27 Results from 1 RCT included in the review suggested that patients treated with prolonged exposure with D-cycloserine were significantly more likely to show treatment response measured post-treatment.27 However, the systematic review also reported results from a different RCT that suggested that the prolonged exposure with D-cycloserine group performed significantly worse on measures of PTSD post treatment.27 Additionally, the review reported mixed results for prolonged exposure with paroxetine versus control groups.27 The systematic review reported results from 1 RCT that suggested there was a significant difference in improvement in PTSD symptoms in favour of the prolonged exposure with paroxetine group versus prolonged exposure alone.27 However, the systematic review also reported results from 2 other RCTs that suggested there were no significant differences for PTSD symptoms between prolonged exposure with paroxetine versus control groups.27

The systematic review by Merz et al. (2019)24 reported no significant difference in PTSD symptom severity measured at the end of treatment (12 weeks) for exposure therapy with fluoxetine versus fluoxetine alone; however, there was a significant difference in PTSD symptom severity in favour of the exposure therapy with fluoxetine group measured at the last available follow-up (length of follow-up not reported) (1 RCT).

Additional Efficacy Outcomes
Several relevant RCTs included in the Metcalf et al. (2020)27 systematic review reported on depression and quality of life. The systematic review reported results from 3 relevant RCTs that suggested there were no significant differences between treatment groups for depression.27 The systematic review also reported results from 1 RCT that suggested that reconsolidation therapy using prolonged exposure with D-cycloserine performed significantly worse on measures of depression than the control group at post treatment.27 Results from a different RCT included in the review suggested there were significant reductions in symptoms of depression within the prolonged exposure with repetitive transcranial magnetic stimulation group.27 There was a significant difference in favour of imaginal exposure with methylene blue versus control in quality of life for mental health (1 RCT).27 The systematic review reported results from another relevant RCT that suggested that the prolonged exposure with paroxetine group had significantly greater improvement in quality of life versus those in the control group.27
Safety

The systematic review by Metcalf et al. (2020) indicates that several of its included relevant RCTs reported adverse events. However, there were limited details on specific adverse events and distribution across study groups.

Eleven relevant RCTs included in the Metcalf et al. (2020) and Merz et al. (2019) systematic reviews evaluated treatment dropout. There were statistically significant differences between treatment groups in dropout in some of the studies and in other studies there were no significant differences between groups. One relevant RCT included in the Metcalf et al. (2020) systematic review evaluated treatment adherence and the results suggested there were statistically significant differences between treatment groups.

Clinical Effectiveness of Consolidation Therapy

PTSD Incidence

The meta-analysis conducted by Bertolini et al. (2022) suggested that there were no significant differences between propranolol and placebo in PTSD rate at 3 months or at the studies’ end point (ranging from 6 weeks to 3 months). Four relevant RCTs included in the systematic review that were not included in the meta-analysis found no significant difference in PTSD rate between other consolidation therapies and control.

The meta-analysis conducted by Astill Wright et al. (2021) pooled results from studies that evaluated various consolidation interventions versus control groups. The meta-analysis suggested there was a statistically significant difference in PTSD incidence at 1 month to 48 months in favour of all pharmacological, and psychological consolidation interventions (pooled result of a range of consolidation therapies) versus control. When studies evaluating hydrocortisone were removed from the analysis there was no significant difference in PTSD incidence at 1 month to 48 months in favour of all pharmaceutical consolidation interventions versus control. PTSD incidence at 3 months to 31 months was statistically significantly different in favour of hydrocortisone versus control. There was no significant difference in PTSD incidence at 1 month to 6 months for cognitive memory task interference procedure versus control.

PTSD Severity

The meta-analysis conducted by Bertolini et al. (2022) suggested that there were no significant differences between propranolol and placebo in PTSD severity at 3 months or at the studies’ end point (ranging from 6 weeks to 3 months). The results for PTSD severity from 6 relevant RCTs evaluating other consolidation therapies were reported individually by study. The systematic review reported the results from 1 RCT that suggested that there is a statistically significant difference in PTSD severity in favour of 5-hydroxytryptophan versus placebo. There were no significant differences between treatment groups in PTSD severity in the other 5 RCTs included in the systematic review that reported on this outcome.

The meta-analysis by Astill Wright et al. (2021) suggested there were no significant differences in PTSD severity at 2 weeks to 6 months or re-experiencing severity at 2 weeks to 48 months for all pharmacological and psychological consolidation interventions versus control. There was no significant difference in PTSD severity at 3 to 6 months for all pharmacological consolidation interventions versus control. Virtual reality pain task showed no significant differences in PTSD severity or re-experiencing severity at 6 months versus
For cognitive memory task interference procedure versus control, there were no significant differences in PTSD severity at 2 weeks to 6 months or re-experiencing severity at 4 weeks.  

**Intrusive Memory Frequency**

The meta-analysis by Astill Wright et al. (2021) suggested that there was a significant difference in intrusive memory frequency at 1 week in favour of cognitive memory task interference procedure versus control.

**Additional Efficacy Outcomes**

Results for depression severity were reported individually for 4 relevant RCTs in the systematic review by Bertolini et al. (2022). There were no significant differences between treatment groups in depression severity in 3 of the RCTs. In 1 of the RCTs there were no significant differences in depression severity assessed at baseline and follow-up.

Results for quality of life were reported individually for 3 relevant RCTs in the systematic review by Bertolini et al. (2022). There were no significant differences in quality of life between the treatment groups in any of the 3 RCTs.

**Safety**

Dropouts due to adverse events were reported in 3 relevant RCTs in the systematic review by Bertolini et al. (2022). In 2 of the RCTs none of the participants dropped out due to adverse events. In 1 RCT there were no significant differences between treatment groups in dropouts rates due to adverse events.

The meta-analysis conducted by Bertolini et al. (2022) suggested there were no significant differences between propranolol and placebo in dropout rates for any reason at 3 months or study end point (ranging from 6 weeks to 3 months). The meta-analysis suggested there were no significant differences between hydrocortisone versus placebo in dropout rates for any reason at study end point (ranging from 6 months to 49 months). The results for dropout for any reason from 4 relevant RCTs evaluating other consolidation therapies were reported individually by study. There were no significant differences between treatment groups in dropout rate for any reason at various time points in the 4 RCTs.

**Limitations**

No evidence was identified that evaluated consolidation therapy for the prevention of acute stress disorder. Additionally, there was very limited evidence on the safety of reconsolidation and consolidation therapies reported in the included systematic reviews.

The relevant primary studies summarized in the included systematic reviews were of variable methodological quality. The systematic review authors’ ratings of the overall certainty of the evidence ranged from very low to low and many of the included primary studies were assessed as having moderate to high risk of bias. The authors of the Knaust et al. (2020) systematic review did not assess the risk of bias in the included primary studies; however, several relevant case studies and a single-arm before-after study were included, and are expected to be at high risk of bias due to the study design.
The relevant primary studies summarized in the included systematic reviews used a wide range of scales to assess PTSD severity. The minimal clinically important differences for these scales were not discussed in the systematic reviews; thus, it is unclear if the magnitude of benefits reported for the reconsolidation and consolidation therapies are clinically meaningful.

Conclusions and Implications for Decision- or Policy-Making

This report summarizes evidence on the clinical effectiveness of reconsolidation therapy for the treatment of PTSD and consolidation therapy for the prevention of PTSD from 2 systematic reviews with meta-analyses,\textsuperscript{22,23} 1 systematic review with a network meta-analysis,\textsuperscript{24} and 3 other systematic reviews\textsuperscript{25-27} that did not combine data from primary studies in a statistical analysis to estimate an overall treatment effect. Four of the systematic reviews\textsuperscript{23,24,26,27} reported on reconsolidation therapy and 2 systematic reviews\textsuperscript{22,23} reported on consolidation therapy.

The reconsolidation therapies varied widely across the included systematic reviews,\textsuperscript{23,24,26,27} and the evaluated interventions included a variety of memory reactivation procedures in combination with a range of pharmacological drugs and nondrug therapies, such as electroconvulsive therapy. The evidence was mixed with the results of some studies suggesting there were statistically significant differences in PTSD severity between patients treated with reconsolidation therapy versus control, and the results from other studies suggesting no significant differences between treatment groups. The meta-analysis conducted by Astill Wright et al. (2021)\textsuperscript{23} suggested there were statistically significant differences in PTSD severity and re-experiencing severity at 1 week to 4 weeks in favour of all pharmacological, electroconvulsive therapy, and psychological reconsolidation interventions versus control. The results of some of the relevant primary studies included in the systematic reviews by Knaust et al. (2020),\textsuperscript{26} Metcalf et al. (2020),\textsuperscript{27} and Merz et al. (2019)\textsuperscript{24} suggested there were significant differences in PTSD symptoms or severity in favour of reconsolidation therapy versus control, whereas results from other studies included in the systematic reviews suggested there were no significant differences between treatment groups. The systematic review by Knaust et al. (2020)\textsuperscript{26} reported that multi-modular motion-assisted memory desensitization and reprocessing therapy reduced PTSD symptoms in veterans with treatment-resistant and combat-related PTSD; however, the significance of these results was not reported. Although 1 systematic reviews\textsuperscript{27} reported primary study level adverse events, information on the specific adverse events was not provided. The other included systematic reviews did not report any safety outcomes\textsuperscript{23,24,27}.

A wide range of consolidation therapies were evaluated in the included systematic reviews.\textsuperscript{22,23} The consolidation interventions evaluated included a range of pharmaceutical drugs, virtual reality pain tasks, and cognitive task memory interference procedures. The evidence was mixed with the results of some studies suggesting there were statistically significant differences in PTSD incidence or severity between patients treated with consolidation therapy versus those in the control group, and results from other studies suggesting there were no significant differences between treatment groups. The meta-analysis conducted by Bertolini et al. (2022)\textsuperscript{22} suggested that there were no significant differences between propranolol and
placebo in PTSD incidence at 3 months or at the studies' end point (ranging from 6 weeks to 3 months). Additionally, the systematic review reported results from relevant RCTs that suggested there were no significant differences in PTSD incidence between omega-3 fatty acids, gabapentin, or paroxetine versus placebo.\textsuperscript{22} The meta-analysis conducted by Astill Wright et al. (2021)\textsuperscript{23} suggested there was a statistically significant difference in PTSD incidence at 1 month to 48 months in favour of all pharmacological and psychological consolidation interventions versus control. However, when studies evaluating hydrocortisone were removed from the analysis, there was no significant difference in PTSD incidence at 1 month to 48 months for all pharmacological and psychological consolidation interventions (without hydrocortisone) versus control.\textsuperscript{23} The results of the meta-analysis suggested there was a statistically significant difference in PTSD incidence at 3 months to 31 months in favour of hydrocortisone versus control.\textsuperscript{23} One of the systematic reviews reported dropouts due to adverse events individually by study for the relevant studies.\textsuperscript{22} The other systematic review did not report any safety outcomes.\textsuperscript{23}

Due to the wide range of heterogeneous reconsolidation and consolidation interventions evaluated in the included systematic reviews, it is difficult to draw conclusions around the clinical effectiveness of reconsolidation therapy for the treatment of PTSD or consolidation therapy for the prevention of PTSD. The limitations of the included literature (e.g., limited safety data, variable quality of primary studies in identified systematic reviews) should be considered when interpreting the findings of this report. Future research that focuses on specific reconsolidation or consolidation therapies or the comparative efficacy of different reconsolidation or consolidation approaches could help determine the clinical effectiveness of reconsolidation therapy for adults with PTSD or the clinical effectiveness of consolidation therapy for the prevention of PTSD or acute stress disorder in adults who have experienced trauma.
References


Appendix 1: Selection of Included Studies

Figure 1: Selection of Included Studies

880 citations identified from electronic literature search and screened

825 citations excluded

55 potentially relevant articles retrieved for scrutiny (full text, if available)

2 potentially relevant reports retrieved from other sources (grey literature, handsearch)

57 potentially relevant reports

51 reports excluded:
- irrelevant population (3)
- irrelevant intervention (8)
- irrelevant study design (25)
- full overlap with a more recent or comprehensive systematic review (9)
- other (review articles, editorials) (6)

6 reports included in review
## Appendix 2: Characteristics of Included Publications

Note that this appendix has not been copy-edited.

### Table 2: Characteristics of Included Systematic Reviews and Meta-Analyses

<table>
<thead>
<tr>
<th>Study citation, country, funding source</th>
<th>Study designs and numbers of primary studies included</th>
<th>Population characteristics</th>
<th>Intervention and comparator(s)</th>
<th>Clinical outcomes, length of follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bertolini et al. (2022)(^{22}) Italy University of York (UK), University of Verona (Italy), NIHR (UK)</td>
<td>Study design: SR and meta-analysis Included studies: 13 RCTs including 12 that are relevant to the present report.</td>
<td>Studies of adults aged 18 and older with history of a traumatic event. Studies that included participants who were symptomatic at baseline were excluded.</td>
<td>Eligible interventions: Any pharmacological intervention administered with the intention to prevent the onset of PTSD or PTSD symptoms within 3 months of the trauma. Eligible comparators: placebo or any active pharmacological agent. Note: 1 included RCT that compared 2 different enteral nutrition formulas is not relevant to the present report.</td>
<td>Outcomes: PTSD severity, PTSD rate, depression severity, quality of life, dropouts due to adverse events, dropout for any reason Follow-up: 2 weeks to 49 months</td>
</tr>
<tr>
<td>Astill Wright et al. (2021)(^{23}) UK Wellcome Trust and Swedish Research Council</td>
<td>Study design: SR and meta-analysis Included studies: 25 RCTs including 24 that are relevant to the present report.</td>
<td>Studies of participants of any age exposed to a traumatic event. Only studies of adults were considered relevant to the present report.</td>
<td>Eligible interventions: consolidation or reconsolidation-based prevention or treatment interventions. Eligible comparators: placebo, pharmacological or psychosocial interventions.</td>
<td>Outcomes: PTSD incidence, PTSD severity, severity of re-experiencing symptoms, intrusive memory severity Follow-up: 1 week to 48 months</td>
</tr>
<tr>
<td>Baas et al. (2020)(^{25}) The Netherlands NR</td>
<td>Study design: SR Included studies: 13 studies including 3 RCTs and 10 non-randomized studies. None of the included studies are relevant to the present report (i.e., none of the studies investigated consolidation or reconsolidation therapy).</td>
<td>Studies of pregnant women with PTSD or exposure to trauma.</td>
<td>Eligible interventions: interventions for the treatment of PTSD not limited to trauma-focused or evidence-based interventions. Eligible comparators: not specified</td>
<td>Outcomes: PTSD diagnosis, PTSD symptoms Follow-up: 6 weeks to 3 years</td>
</tr>
<tr>
<td>Study citation, country, funding source</td>
<td>Study designs and numbers of primary studies included</td>
<td>Population characteristics</td>
<td>Intervention and comparator(s)</td>
<td>Clinical outcomes, length of follow-up</td>
</tr>
<tr>
<td>----------------------------------------</td>
<td>------------------------------------------------------</td>
<td>-----------------------------</td>
<td>-------------------------------</td>
<td>--------------------------------------</td>
</tr>
<tr>
<td>Knaust et al. (2020) Germany University Hospital Hamburg-Eppendorf</td>
<td>Study design: SR Included studies: 18 studies including 6 RCTs, 1 single-arm before-after study, and 3 case studies that are relevant to the present report.</td>
<td>Studies of adults between the ages of 18 and 65 years diagnosed with PTSD.</td>
<td>Eligible interventions: any virtual trauma intervention with the goal to reduce PTSD symptoms that used immersive technology. Eligible comparators: not specified Relevant interventions: 3MDR; VRET with transcranial direct current stimulation; VRET with D-cycloserine; VRET with dexamethasone; VRET with alprazolam</td>
<td>Outcomes: PTSD severity, PTSD symptoms Follow-up: 1 month to 12 months</td>
</tr>
<tr>
<td>Metcalf et al. (2020) Australia Centenary of Anzac Centre, a Department of Veterans’ Affairs funded initiative of Phoenix Australia</td>
<td>Study design: SR Included studies: 34 RCTs including 12 that are relevant to the current report</td>
<td>Studies of adults with diagnosed PTSD.</td>
<td>Eligible interventions: Any first-line PTSD treatment in combination with an augmentation intervention (any psychological, non-psychological, or pharmacological intervention, delivered before, concurrently, or after a first-line PTSD treatment) Eligible comparators: first-line PTSD treatment alone Relevant interventions: prolonged exposure therapy with rTMS, D-cycloserine, intranasal oxytocin, yohimbine, hydrocortisone, methylene blue, paroxetine, or sertraline</td>
<td>Outcomes: PTSD symptoms, PTSD severity, depression, anxiety, rate of remission, response rate, quality of life, treatment dropout, adverse events Follow-up: NR</td>
</tr>
<tr>
<td>Merz et al. (2019) Switzerland NR</td>
<td>Study design: SR and network meta-analysis Included studies: 12 RCTs including 6 that are relevant to the present report.</td>
<td>Studies of adults with PTSD.</td>
<td>Eligible interventions: psychotherapeutic treatments, pharmacological treatments, or combinations of both. Eligible comparators: Any active psychotherapeutic or pharmacological PTSD treatment.</td>
<td>Outcomes: PTSD symptom severity, patient dropouts Follow-up: NR</td>
</tr>
<tr>
<td>Study citation, country, funding source</td>
<td>Study designs and numbers of primary studies included</td>
<td>Population characteristics</td>
<td>Intervention and comparator(s)</td>
<td>Clinical outcomes, length of follow-up</td>
</tr>
<tr>
<td>----------------------------------------</td>
<td>-----------------------------------------------------</td>
<td>----------------------------</td>
<td>-------------------------------</td>
<td>----------------------------------------</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Relevant interventions: prolonged exposure therapy with sertraline or paroxetine; exposure therapy with fluoxetine</td>
<td></td>
</tr>
</tbody>
</table>

3MDR = multi-modular motion-assisted memory desensitization and reconsolidation; NIHR = National Institute for Health Research; NR = not reported; PTSD = post-traumatic stress disorder; RCT = randomized controlled trial; rTMS = repetitive transcranial magnetic stimulation; SR = systematic review; VRET = virtual reality exposure therapy.
Appendix 3: Critical Appraisal of Included Publications

Note that this appendix has not been copy-edited.

Table 3: Strengths and Limitations of Systematic Reviews and Meta-Analyses Using AMSTAR 2

<table>
<thead>
<tr>
<th>Strengths</th>
<th>Limitations</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bertolini et al. (2022)</strong></td>
<td>• Subgroup analyses excluding studies at high risk of bias from the meta-analysis were pre-planned however they could not be carried out due to lack of data</td>
</tr>
<tr>
<td>• Clear objective and inclusion criteria that included components of population, intervention, comparator, and outcomes</td>
<td>• Publication bias could not be assessed through funnel plots due to the low number of studies per comparison</td>
</tr>
<tr>
<td>• The review methods were established before conducting the review and the protocol was published</td>
<td></td>
</tr>
<tr>
<td>• The choice of study designs included in the review (i.e., RCTs) was explained</td>
<td></td>
</tr>
<tr>
<td>• Search was conducted in multiple databases and trial registries, key search terms used were provided, and the reference lists of included articles were hand-searched for additional literature</td>
<td></td>
</tr>
<tr>
<td>• Study selection and data extraction were performed independently by 2 reviewers</td>
<td></td>
</tr>
<tr>
<td>• List of excluded studies and justifications for exclusion were provided</td>
<td></td>
</tr>
<tr>
<td>• Included studies were described in adequate detail</td>
<td></td>
</tr>
<tr>
<td>• The risk of bias in included primary studies was assessed independently by 2 reviewers using a satisfactory technique</td>
<td></td>
</tr>
<tr>
<td>• Funding sources of individual studies included in the review were reported</td>
<td></td>
</tr>
<tr>
<td>• Random effects model used to perform meta-analysis due to clinical heterogeneity</td>
<td></td>
</tr>
<tr>
<td>• Funding sources for review were reported</td>
<td></td>
</tr>
<tr>
<td>• Potential conflicts of interest were disclosed</td>
<td></td>
</tr>
<tr>
<td>• Sources of funding of individual studies included in the review were reported</td>
<td></td>
</tr>
<tr>
<td>• Results from studies assessing a wide range of heterogenous interventions and comparators were combined in meta-analysis which may not have been appropriate</td>
<td></td>
</tr>
<tr>
<td>• Potential conflicts of interest were assessed</td>
<td></td>
</tr>
<tr>
<td>• Frailty and cognitive impairment were not assessed</td>
<td></td>
</tr>
<tr>
<td>• Potential conflicts of interest were not assessed</td>
<td></td>
</tr>
<tr>
<td><strong>Astill Wright et al. (2021)</strong></td>
<td></td>
</tr>
<tr>
<td>• Clear objective and inclusion criteria that included components of population, intervention, comparator, and outcomes</td>
<td></td>
</tr>
<tr>
<td>• The review methods were established before conducting the review and the protocol was registered</td>
<td></td>
</tr>
<tr>
<td>• The choice of study designs included in the review (i.e., RCTs) was explained</td>
<td></td>
</tr>
<tr>
<td>• Search was conducted in multiple databases and trial registries, key search terms used were provided, and the reference lists of narrative reviews and recent systematic reviews were hand-searched for additional literature</td>
<td></td>
</tr>
<tr>
<td>• Study selection and data extraction were performed in duplicate</td>
<td></td>
</tr>
<tr>
<td>• Population, outcomes, design, setting, and time frame for follow-up of included primary studies were described in adequate detail</td>
<td></td>
</tr>
<tr>
<td>• A list of excluded studies was not provided, however, the reasons for exclusion were provided</td>
<td></td>
</tr>
<tr>
<td>• Sources of funding for individual studies included in review were not reported</td>
<td></td>
</tr>
<tr>
<td>• Results from studies assessing a wide range of heterogenous interventions and comparators were combined in meta-analysis which may not have been appropriate</td>
<td></td>
</tr>
<tr>
<td>• Authors did not perform sensitivity analyses to assess impact of risk of bias in individual studies on results of meta-analysis</td>
<td></td>
</tr>
<tr>
<td>• Authors did not state whether they assessed publication bias</td>
<td></td>
</tr>
</tbody>
</table>
### Strengths

- The risk of bias in included primary studies was assessed independently by 2 reviewers using a satisfactory technique
- Heterogeneity was assessed through several sensitivity analyses of subgroups of various interventions
- Funding sources for review were reported
- Potential conflicts of interest were disclosed

### Limitations

- Eligible comparators were not specified
- Abstract screening was performed by 1 reviewer
- List of excluded studies not provided, however reasons for exclusion were provided

### Baas et al. (2020)

- Clear objective and inclusion criteria that included components of population, intervention, and outcomes
- The review methods were established before conducting the review and the protocol was registered
- The choice of study designs included in the review (i.e., non-randomized studies and RCTs) was explained
- Search was conducted in multiple databases, key search terms used were provided, and the reference lists of included articles were handsearched for additional literature
- Full text screening was performed independently by 2 reviewers

### Knaust et al. (2020)

- Clear objective and inclusion criteria that included components of population, intervention, and outcomes
- The choice of study designs included in the review (i.e., non-randomized studies and RCTs) was explained
- Search was conducted in multiple databases and trial registries, and key search terms used were provided
- Study selection performed in duplicate
- Population, outcomes, design, setting, and time frame for follow-up of included primary studies described in adequate detail
- Funding source for review was reported
- Authors state that they had no conflicts of interest

### Metcalf et al. (2020)

- Clear objective and inclusion criteria that included components of population, intervention, comparator, and outcomes
- The choice of study designs included in the review (i.e., controlled trials) was explained
- Search was conducted in multiple databases and trial registries, and key search terms used were provided
- One reviewer extracted data and a second reviewer checked the data
- Population, interventions, comparators, outcomes, and design of included primary studies described in adequate detail
- Risk of bias in included studies was assessed independently by

### Notes

- The authors do not state whether the review methods were established before conducting the review
- The authors do not state whether the reference lists of included articles were hand-searched to identify additional literature
- Unclear whether study selection was performed in duplicate
- A list of excluded studies was not provided, however, the reasons for exclusion were provided
- Risk of bias in included primary studies was not assessed
- Sources of funding for individual studies included in the review not reported

- Sources of funding for individual studies included in the
### Strengths

- 2 reviewers using a satisfactory technique
- Funding source for review was reported

### Limitations

- Review not reported
- The authors do not state whether they had any potential conflicts of interest

**Merz et al. (2019)**

- Clear objective and inclusion criteria that included components of population, intervention, comparator, and outcomes
- The review methods were established before conducting the review and the protocol was registered
- The choice of study designs included in the review (i.e., RCTs) was explained
- The search was conducted in multiple databases and trial registries, key search terms used were provided, and reference lists of included articles were hand-searched for additional literature
- Full text screening and data extraction were performed independently by 2 reviewers
- Population, interventions, comparators, outcomes, and design of included primary studies described in adequate detail
- Risk of bias in included primary studies was assessed using a satisfactory technique
- Potential conflicts of interest disclosed

- Unclear whether abstract screening was performed in duplicate
- A list of excluded studies was not provided, however, the reasons for exclusion were provided
- The countries and time frame for follow-up of included primary studies were not specified
- Sources of funding for individual studies included in the review not reported
- Funding source for review not reported

*AMSTAR 2 = A MeaSurement Tool to Assess systematic Reviews 2; RCT = randomized controlled trial.*
## Table 4: Summary of Findings by Outcome — PTSD, Depression, and Anxiety (Reconsolidation Therapy)

<table>
<thead>
<tr>
<th>Study citation and study design</th>
<th>Intervention/comparison</th>
<th>Detailed findings</th>
</tr>
</thead>
</table>
| Astill Wright et al. (2021)\(^{23}\) SR and meta-analysis | All pharmacological, electroconvulsive therapy, and psychological reconsolidation interventions vs control | PTSD severity at 1 to 4 weeks (9 RCTs; n = 372)  
- SMD = −1.42 (95% CI, −2.25 to −0.58)  
SMD < 0 favours pharmacological, electroconvulsive therapy, psychological reconsolidation interventions  
Re-experiencing severity at 1 to 4 weeks (7 RCTs; n = 235)  
- SMD = −2.29 (95% CI, −3.55 to −1.04)  
SMD < 0 favours pharmacological, electroconvulsive therapy, psychological reconsolidation interventions |
| | All pharmacological, and electroconvulsive therapy reconsolidation interventions vs control | PTSD severity at 1 to 4 weeks (5 RCTs; n = 215)  
- SMD = −0.26 (95% CI, −0.60 to 0.08)  
SMD < 0 favours pharmacological, electroconvulsive therapy reconsolidation interventions |
| | Propranolol with MR vs control | PTSD severity at 1 week (2 RCTs; n = 78)  
- SMD = 0.32 (95% CI, −0.93 to 1.56)  
SMD < 0 favours propranolol with MR |
| | Reconsolidation of traumatic memories vs waitlist control | PTSD severity at 2 weeks (4 RCTs; n = 157)  
- SMD = −3.64 (95% CI, −5.07 to −2.20)  
SMD < 0 favours reconsolidation of traumatic memories  
Re-experiencing severity at 2 weeks (4 RCTs; n = 157)  
- SMD = −3.60 (95% CI, −4.85 to −2.35)  
SMD < 0 favours reconsolidation of traumatic memories |
| Knaust et al. (2020)\(^{26}\) SR (6 RCTs, 1 single-arm before-after study, 3 case studies) | VRET with D-cycloserine vs VRET with placebo | Difede et al. 2013 (RCT)  
- CAPS measured post-treatment  
  - Hedges’ g = 0.68 (favours VRET with D-cycloserine)  
- CAPS measured at 6 months  
  - Hedges’ g = 1.13  
*Significant decrease on the CAPS for both treatment groups. At 6 month-follow-up VRET with D-cycloserine were superior to active control group (p. 8).*\(^{26}\)  
VRET with dexamethasone vs VRET with placebo | Maples-Keller et al. 2018 (RCT)  
*Significant decrease on the CAPS for post-treatment but no significant differences between groups (p. 9).*\(^{26}\)  
"Significant decrease on the CAPS for both treatment groups. At 6 month-follow-up VRET with D-cycloserine were superior to active control group (p. 8).*\(^{26}\)
<table>
<thead>
<tr>
<th>Study citation and study design</th>
<th>Intervention/ comparison</th>
<th>Detailed findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rothbaum et al. 2014 (RCT)</td>
<td>VRET with D-cycloserine vs VRET with alprazolam vs VRET with placebo</td>
<td><em>All groups decreased significantly on the CAPS. The effect maintained over 12 months-follow-up. At post-treatment there was no significant difference between D-cycloserine and placebo group on the CAPS. However, there was a significant difference favoring placebo over alprazolam regarding the CAPS at post-treatment (p &lt; .05).</em></td>
</tr>
</tbody>
</table>
| Van't Wout et al. 2018 (RCT) | VRET with tDCS vs VRET with sham tDCS | • PCL-5 measured post-treatment  
  - Hedges’ g = 0.20 (favours VRET with tDCS)  
  - PCL-5 measured at 1 month  
  - Cohen’s d = 0.37  
  *Both groups demonstrated significant reductions in PCL scores. There were no significant differences between groups at post time measurement, but VRET with tDCS were superior to VRET sham tDCS at 1 month-follow-up (p < .05).* |
| Bisson et al. 2020 (RCT) | 3MDR vs waitlist | • CAPS-5 measured at 12 weeks  
  - Cohen’s d = 0.65 (favours 3MDR)  
  *Results indicated that 3MDR reduces PTSD symptoms in Veterans with treatment-resistant and combat-related PTSD (p < .05).* |
| Van Gelderen et al. 2020 (RCT) | 3MDR vs non-trauma focused treatment (e.g., case management, stabilizing interventions, psychoeducation, etc.) | • CAPS-5 measured at 16 weeks  
  - Cohen’s d = 0.83 (favours 3MDR)  
  *Results showed that 3MDR reduces PTSD symptoms in Veterans with treatment-resistant and combat-related PTSD. However, no significant differences were found for secondary outcomes measures (e.g., PCL-5) and no long-term effects were assessed (p > .05).* |
<p>| Jetly et al. 2017 (single-arm before-after study) | 3MDR | <em>Modest therapy gains for patients with treatment-resistant and combat-related PTSD (p &lt; .05).</em> |
| Nijdam and Vermetten 2018 (case study) | | <em>Positive treatment results for a single patient with treatment-resistant and combat-related PTSD (p &lt; .05).</em> |
| Van Gelderen et al. 2018 (case study) | | <em>Positive treatment results for three patients with treatment-resistant and combat-related PTSD (p &lt; .05).</em> |
| Vermetten et al. 2013 (case study) | | <em>Preliminary results of two cases suggest that 3MDR is perhaps a treatment for treatment-resistant and combat-related PTSD (p &lt; .05).</em> |
| Metcalf et al. (2020) | PE with rTMS vs PE alone | <em>PE + rTMS produced significant reductions in symptoms of depression in the fourth and fifth PE sessions (p ≤ .013) and a 15% greater reduction in CAPS scores at session five (p &lt; .05).</em> |</p>
<table>
<thead>
<tr>
<th>Study citation and study design</th>
<th>Intervention/comparison</th>
<th>Detailed findings</th>
</tr>
</thead>
</table>
| condition refers to the experimental group (i.e., either PE or IE in combination with a pharmacological agent). | PE with D-cycloserine vs PE alone | De Kleine et al. 2012

“No difference in PTSD symptoms between conditions; those in augmentation condition were more likely to show treatment response posttreatment ($p = .040$, OR $= 2.83$) (p. 8)"\(^{27}\)

Litz et al. 2012

“The augmentation condition performed significantly worse on measures of PTSD and depression at posttreatment ($p < .05$, $g = 0.40–0.73$). There were no significant effects at three- or six-month follow-up ($p > .100$) (p. 8)."\(^{27}\)
| PE with intranasal oxytocin vs PE alone | Flanagan et al. 2018

“No significant differences between conditions ($p > .050$) (p. 8)."\(^{27}\)
| PE with yohimbine vs PE alone | Tuerk et al. 2018

“No differences between conditions in PTSD symptom reduction, remission rate, or depression (p. 9)."\(^{27}\)
| PE with hydrocortisone vs PE alone | Yehuda et al. 2013

“PTSD symptoms change was greater for the augmentation condition ($p < .050$, $d = 0.43$); no differences between conditions posttreatment (p. 9)."\(^{27}\)
| IE with methylene blue vs IE alone | Zoellner et al. 2017

There were no significant differences between groups on measures of PTSD severity or diagnosis, or depression.
| PE with paroxetine vs PE alone vs paroxetine alone | Popiel et al. 2015

- PTSD remission rate
  - PE with paroxetine: 51.2%
  - PE alone: 65.4%
  - Paroxetine alone: 43.3%
  - PE with paroxetine vs PE alone: $P = 0.110$
  - PE with paroxetine vs paroxetine alone: $P = 0.510$

There were significant improvements in self-rated PTSD symptoms in all groups, and improvements were maintained at 12-month follow-up. However, there were no significant differences between groups in self-rated PTSD symptoms.
| PE with sertraline vs PE alone vs sertraline alone | Rauch et al. 2019

“PTSD significantly improved for all conditions ($p < .001$); with no differences in PTSD symptom reduction ($p \geq .050$), response rates ($p = .360$), or remission rates ($p = .180$) (p. 10)"\(^{27}\)
<table>
<thead>
<tr>
<th>Study citation and study design</th>
<th>Intervention/comparison</th>
<th>Detailed findings</th>
</tr>
</thead>
</table>
| PE with sertraline vs sertraline alone | Rothbaum et al. 2006 | “There was no difference between conditions in PTSD symptom reduction, depression, or anxiety at any time point (p > .050) (p. 10).”
| PE with paroxetine vs PE alone | Schneier et al. 2012 | • PTSD remission rate  
  o PE with paroxetine: 42.1%  
  o PE alone: 16.7%  
  o P value for difference = 0.030  
  • Response rate  
  o PE with paroxetine: 63.2%  
  o PE alone: 38.9%  
  o P value for difference = 0.040  
  There was a significant difference between treatment groups in improvement in PTSD symptoms favouring the PE with paroxetine group (P = 0.010).
| Merz et al. (2019)\(^{24}\) SR (1 RCT) | ET with fluoxetine vs fluoxetine alone | Su et al. 2007  
  • PTSD symptom severity (measured with PCL) at the end of treatment  
  o SMD = 0.14 (95% CI, −0.74 to 1.02)  
  • PTSD symptom severity (measured with PCL) at the last available follow-up  
  o SMD = −1.99 (95% CI, −3.11 to −0.88)  
  SMD < 0 favours ET with fluoxetine

3MDR = multi-modular motion-assisted memory desensitization and reconsolidation; CAPS = clinician-administered PTSD scale; CAPS-5 = clinician-administered PTSD scale for Diagnostic and Statistical Manual of Mental Disorders 5th Edition; CI = confidence interval; ET = exposure therapy; IE = imaginal exposure; MR = memory reactivation; OR = odds ratio; PCL = PTSD checklist; PCL-5 = PTSD checklist for Diagnostic and Statistical Manual of Mental Disorders 5th Edition; PE = prolonged exposure; PTSD = post-traumatic stress disorder; RCT = randomized controlled trial; rTMS = repetitive transcranial magnetic stimulation; SMD = standardized mean difference; SR = systematic review; tDCS = transcranial direct current stimulation; VRET = virtual reality exposure therapy.
### Table 5: Summary of Findings by Outcome — Treatment Dropout and Adherence (Reconsolidation Therapy)

<table>
<thead>
<tr>
<th>Study citation and study design</th>
<th>Comparison</th>
<th>Detailed findings</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Treatment dropout</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| Metcalf et al. (2020) SR (10 RCTs) | PE with D-cycloserine vs PE alone | De Kleine et al. 2012  
No significant differences between groups in dropout.  
Litz et al. 2012  
• PE with D-cycloserine: 30.8%  
• PE alone: 15.4% |
| PE with intranasal oxytocin vs PE alone | Flanagan et al. 2018  
• PE with oxytocin: 25%  
• PE alone: 22.2% |
| PE with yohimbine vs PE alone | Tuerk et al. 2018  
• PE with yohimbine: 35.7%  
• PE alone: 33.3% |
| PE with hydrocortisone vs PE alone | Yehuda et al. 2013  
• PE with hydrocortisone: 8.3%  
• PE alone: 58.3%  
• P value for difference = 0.027 |
| IE with methylene blue vs IE alone | Zoellner et al. 2017  
• IE with methylene blue: 33.3%  
• IE alone: 6.3% |
| PE with paroxetine vs PE alone vs paroxetine alone | Popiel et al. 2015  
• PE with paroxetine: 22.8%  
• PE alone: 18.4%  
• Paroxetine alone: 12.2% |
| PE with sertraline vs sertraline alone | Rothbaum et al. 2006  
• PE with sertraline: 18%  
• Sertraline alone: 3%  
• P value for difference > 0.050 |
| PE with paroxetine vs PE alone | Schneier et al. 2012  
• PE with paroxetine: 31.6%  
• PE alone: 27.8% |
| | Simon et al. 2008  
• PE with paroxetine: 27.3%  
• PE alone: 14.3% |
<table>
<thead>
<tr>
<th>Study citation and study design</th>
<th>Comparison</th>
<th>Detailed findings</th>
</tr>
</thead>
</table>
| Merz et al. (2019)\(^{24}\) SR (1 RCT) | ET with fluoxetine vs fluoxetine alone | Su et al. 2007  
OR = 1.00 (95% CI, 0.02 to 55.8)  
OR < 1 favours ET with fluoxetine |
| Metcalf et al. (2020)\(^{27}\) SR (1 RCT) | PE with sertraline vs PE alone vs sertraline alone | Rauch et al. 2019  
- PE with sertraline: 53.6%  
- PE alone: 46.3%  
- Sertraline alone: 73.2%  
- P value for difference = 0.005 |

CI = confidence interval; ET = exposure therapy; IE = imaginal exposure; OR = odds ratio; PE = prolonged exposure; RCT = randomized controlled trial; SR = systematic review.
Table 6: Summary of Findings by Outcome — Additional Outcomes (Reconsolidation Therapy)

<table>
<thead>
<tr>
<th>Study citation and study design</th>
<th>Comparison</th>
<th>Detailed findings</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Adverse events</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| Metcalf et al. (2020)\[27\]     | PE with D-cycloserine vs PE alone | De Kleine et al. 2012  
One participant from each treatment group was excluded due to adverse events.  
Litz et al. 2012  
Three participants in the PE with D-cyclosporine group reported clinically significant symptom worsening. |
| SR (6 RCTs)                     | PE with intranasal oxytocin vs PE alone | Flanagan et al. 2018  
One adverse event was reported in the PE alone group. |
|                                 | PE with yohimbine vs PE alone | Tuerk et al. 2018  
One participant in the PE with yohimbine group administered rescue medication before the treatment session. |
|                                 | IE with methylene blue vs IE alone | Zoellner et al. 2017  
One participant in the IE with methylene blue group discontinued due to adverse events. |
|                                 | PE with paroxetine vs PE alone | Simon et al. 2008  
There were 2 adverse events that led to treatment discontinuation in the PE alone group and 1 adverse event that led to treatment discontinuation in the PE with paroxetine group. |
| **Quality of life**             |            |                  |
| Metcalf et al. (2020)\[27\]     | IE with methylene blue vs IE alone | Zoellner et al. 2019  
There were no significant differences between groups negative beliefs, disability, or quality of life (physical vitality) at 3-month follow-up. Quality of life (mental health) was greater in the IE and methylene blue group (P = 0.020, d = 0.58). |
| SR (2 RCTs)                     | PE with paroxetine vs PE alone | Schneier et al. 2012  
Participants in the PE and paroxetine group had greater improvement in quality of life (P = 0.020). |

IE = imaginal exposure; PE = prolonged exposure; RCT = randomized controlled trial; SR = systematic review.
### Table 7: Summary of Findings by Outcome — PTSD (Consolidation Therapy)

<table>
<thead>
<tr>
<th>Study citation and study design</th>
<th>Comparison</th>
<th>Detailed findings</th>
</tr>
</thead>
</table>
| Bertolini et al. (2022)²²       | Propranolol vs placebo | **PTSD incidence**  
  - PTSD rate at 3 months (3 RCTs; n = 88)  
    • RR = 0.77 (95% CI, 0.31 to 1.92; P = 0.58)  
    RR < 1 favours propranolol  
  - PTSD rate at studies’ end point (4 RCTs; n = 127)  
    • RR = 0.73 (95% CI, 0.35 to 1.51; P = 0.39)  
    RR < 1 favours propranolol |
| Omega-3 fatty acids vs placebo  | Matsuoka et al. 2015 (RCT) | PTSD rate at 3 months  
  • RR = 2.44 (95% CI, 0.23 to 26.09; P = 0.46)  
  RR < 1 favours omega-3 fatty acids |
| Propranolol vs gabapentin       | Stein et al. 2007 (RCT) | PTSD rate at 3 months  
  • RR = 1.25 (95% CI, 0.26 to 6.07; P = 0.78)  
  RR < 1 favours propranolol |
| Gabapentin vs placebo           | Stein et al. 2007 (RCT) | PTSD rate at 3 months  
  • RR = 0.80 (95% CI, 0.18 to 3.59; P = 0.77)  
  RR < 1 favours gabapentin |
| Paroxetine vs placebo           | Borelli et al. 2019 (RCT) | PTSD rate at 12 months  
  • Paroxetine: 17.7%  
  • Placebo: 16.7%  
  • P-value for difference = 0.939 |
| Astill Wright et al. (2021)²³  | All pharmacological, and psychological consolidation interventions vs control | PTSD incidence at 1 to 48 months (12 RCTs; n = 2821)  
  • RR = 0.67 (95% CI, 0.50 to 0.90)  
  RR < 1 favours pharmacological, psychological consolidation interventions |
|                                 | All pharmacological, and psychological consolidation interventions (without hydrocortisone) vs control | PTSD incidence at 1 to 48 months (7 RCTs; n = 2695)  
  • RR = 0.75 (95% CI, 0.55 to 1.03)  
  RR < 1 favours pharmacological, psychological consolidation interventions (without hydrocortisone) |
|                                 | All pharmacological consolidation interventions vs control | PTSD incidence at 3 to 48 months (10 RCTs; n = 2771)  
  • RR = 0.69 (95% CI, 0.52 to 0.93)  
  RR < 1 favours pharmacological interventions |
<table>
<thead>
<tr>
<th>Study citation and study design</th>
<th>Comparison</th>
<th>Detailed findings</th>
</tr>
</thead>
</table>
| Hydrocortisone vs control | PTSD incidence at 3 to 31 months (5 RCTs; n = 126) | • RR = 0.32 (95% CI, 0.14 to 0.74)  
RR < 1 favours hydrocortisone |
| Cognitive memory task interference procedure with MR vs control | PTSD incidence at 1 to 6 months (3 RCTs; n = 157) | • RR = 0.45 (95% CI, 0.05 to 4.18)  
RR < 1 favours cognitive memory task interference procedure with MR |

**PTSD severity**

<table>
<thead>
<tr>
<th>Study citation and study design</th>
<th>Comparison</th>
<th>Detailed findings</th>
</tr>
</thead>
</table>
| Bertolini et al. (2022)²² SR and meta-analysis | Propranolol vs placebo | PTSD severity at 3 months (2 RCTs; n = 86)  
• SMD = −0.51 (95% CI, −1.61 to 0.59; P = 0.36)  
SMD < 0 favours propranolol |
| | PTSD severity at studies’ end point (4 RCTs; n = 125) | • SMD = −0.42 (95% CI, −1.16 to 0.32; P = 0.27)  
SMD < 0 favours propranolol |
| Shaked et al. 2019 (RCT) | Hydrocortisone vs placebo | PTSD severity at 1 month  
• MD = 4.36 (95% CI, −0.71 to 9.43; P = 0.09)  
MD < 0 favours hydrocortisone |
| Matsuoka et al. 2015 (RCT) | Omega-3 fatty acids vs placebo | PTSD severity at 3 months  
• MD = 1.56 (95% CI, −4.06 to 7.18; P = 0.59)  
MD < 0 favours omega-3 fatty acids |
| Stein et al. 2007 (RCT) | Propranolol vs gabapentin | PTSD severity at 3 months  
• There were no significant differences between the propranolol and gabapentin groups in reduction of PTSD symptoms over time. |
| Stein et al. 2007 (RCT) | Gabapentin vs placebo | PTSD severity at 3 months  
• There were no significant differences between the gabapentin and placebo groups in reduction of PTSD symptoms over time. |
| Borelli et al. 2019 (RCT) | Paroxetine vs placebo | Mean change in PCL-C score from baseline to 3 months  
• Paroxetine: −4.0  
• Placebo: 0.3 |
| | | Mean change in PCL-C score from baseline to 6 months  
• Paroxetine: −4.4  
• Placebo: −0.5  
• P-value for difference = 0.873 |
<table>
<thead>
<tr>
<th>Study citation and study design</th>
<th>Comparison</th>
<th>Detailed findings</th>
</tr>
</thead>
</table>
| Astill Wright et al. (2021)\textsuperscript{23} \SR and meta-analysis | 5-hydroxytryptophan vs placebo | Tincu et al. 2016 (RCT) PTSD severity at 14 days  
- The mean CAPS score at follow-up was significantly higher in the placebo group than the 5-hydroxytryptophan group (P = 0.006). |
| Astill Wright et al. (2021)\textsuperscript{23} \SR and meta-analysis | All pharmacological, and psychological consolidation interventions vs control | PTSD severity at 2 weeks to 6 months (8 RCTs; n = 411)  
- SMD = −0.12 (95% CI, −0.31 to 0.08)  
SMD < 0 favours pharmacological, psychological consolidation interventions  
Re-experiencing severity at 2 weeks to 48 months (6 RCTs; n = 1,421)  
- SMD = −0.12 (95% CI, −0.37 to 0.13)  
SMD < 0 favours pharmacological, psychological consolidation interventions  
PTSD severity at 3 to 6 months (4 RCTs; n = 202)  
- SMD = −0.25 (95% CI, −0.53 to 0.03)  
SMD < 0 favours pharmacological consolidation interventions  
Virtual reality pain task vs control | PTSD severity at 6 months (1 RCT; n = 55)  
- SMD = −0.46 (95% CI, −0.99 to 0.08)  
SMD < 0 favours virtual reality pain task  
Re-experiencing severity at 6 months (1 RCT; n = 55)  
- SMD = 0.14 (95% CI, −0.39 to 0.67)  
SMD < 0 favours virtual reality pain task  |
| Cognitive memory task interference procedure with MR vs control | PTSD severity at 2 weeks to 6 months (3 RCTs; n = 154)  
- SMD = −0.08 (95% CI, −0.40 to 0.23)  
SMD < 0 favours cognitive memory task interference procedure with MR  
Re-experiencing severity at 4 weeks (2 RCTs; n = 127)  
- SMD = −0.25 (95% CI, −0.60 to 0.10)  
SMD < 0 favours cognitive memory task interference procedure with MR |

### Intrusive memory frequency

<table>
<thead>
<tr>
<th>Study citation and study design</th>
<th>Comparison</th>
<th>Detailed findings</th>
</tr>
</thead>
</table>
| Astill Wright et al. (2021)\textsuperscript{23} \SR and meta-analysis | Cognitive memory task interference procedure with MR vs control | Intrusive memory frequency at 1 week (3 RCTs; n = 166)  
- SMD = −0.49 (95% CI, −0.80 to −0.18)  
SMD < 0 favours cognitive memory task interference procedure with MR |

CAPS = clinician-administered post-traumatic stress disorder scale; CI = confidence interval; MD = mean difference; MR = memory reactivation; PCL-C = post-traumatic stress disorder checklist - civilian version; PTSD = post-traumatic stress disorder; RCT = randomized controlled trial; RR = relative risk; SMD = standardized mean difference; SR = systematic review.
Table 8: Summary of Findings by Outcome — Treatment Dropout (Consolidation Therapy)

<table>
<thead>
<tr>
<th>Study citation and study design</th>
<th>Comparison</th>
<th>Detailed findings</th>
</tr>
</thead>
</table>
| Bertolini et al. (2022)²²       | Propranolol vs placebo | Orrey et al. 2015 (RCT) Dropouts due to adverse events at 6 weeks  
|                                 |                   |  • RR = 5.21 (95% CI, 0.26 to 102.98; P = 0.28) RR < 1 favours propranolol       |
|                                 | Omega-3 fatty acids vs placebo | Matsuoka et al. 2015 (RCT) No participants dropped out due to adverse events in either treatment group. |
|                                 | Propranolol vs gabapentin | Stein et al. 2007 (RCT) No participants discontinued the assigned medication due to adverse events during the first treatment week. |
| Bertolini et al. (2022)²²       | Propranolol vs placebo | Dropout for any reason at 3 months (3 RCTs; n = 118)  
|                                 |                   |  • RR = 1.53 (95% CI, 0.77 to 3.01; P = 0.22) RR < 1 favours propranolol       |
|                                 | Hydrocortisone vs placebo | Dropout for any reason at study end point (2 RCTs; n = 60)  
|                                 |                   |  • RR = 1.38 (95% CI, 0.49 to 3.89; P = 0.54) RR < 1 favours hydrocortisone   |
|                                 | Dexamethasone vs placebo | Kok et al. 2016 (RCT) Dropout for any reason at 1.5 to 4 years  
|                                 |                   |  • RR = 0.93 (95% CI, 0.66 to 1.31; P = 0.68) RR < 1 favours dexamethasone   |
|                                 | Omega-3 fatty acids vs placebo | Matsuoka et al. 2015 (RCT) Dropout for any reason at 3 months  
|                                 |                   |  • RR = 4.30 (95% CI, 0.96 to 19.35; P = 0.06) RR < 1 favours omega-3 fatty acids |
|                                 | Propranolol vs gabapentin | Stein et al. 2007 (RCT) Dropout for any reason at 3 months  
|                                 |                   |  • RR = 1.03 (95% CI, 0.34 to 3.12; P = 0.96) RR < 1 favours propranolol     |
|                                 | Gabapentin vs placebo | Stein et al. 2007 (RCT) Dropout for any reason at 3 months  
|                                 |                   |  • RR = 4.86 (95% CI, 0.61 to 38.65; P = 0.14) RR < 1 favours gabapentin     |

CI = confidence interval; RCT = randomized controlled trial; RR = relative risk; SMD = standardized mean difference; SR = systematic review.
# Table 9: Summary of Findings by Outcome — Additional Outcomes (Consolidation Therapy)

<table>
<thead>
<tr>
<th>Study citation and study design</th>
<th>Comparison</th>
<th>Detailed findings</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Depression severity</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| Bertolini et al. (2022)²²       | Omega-3 fatty acids vs placebo | Matsuoka et al. 2015 (RCT) MADRS score at 3 months  
  \* MD = 1.82 (95% CI, -1.65 to 5.29; P = 0.30)  
  MD < 0 favours omega-3 fatty acids |
|                                 | Propranolol vs placebo | Stein et al. 2007 (RCT) Over the course of the study CES-D scores did not differ significantly between treatment groups. |
|                                 | Gabapentin vs placebo | Stein et al. 2007 (RCT) CES-D scores measured at 3 months did not differ significantly between treatment groups. |
|                                 | Paroxetine vs placebo | Borelli et al. 2019 (RCT) There were no significant differences between QIDS-SR scores assessed at baseline and follow-up at 8 weeks. |
| **Quality of life**             |            |                  |
| Bertolini et al. (2022)²²       | Dexamethasone vs placebo | Kok et al. 2016 (RCT) There were no significant differences between treatment groups in SF-36 Mental Component Summary scores. |
|                                 | Omega-3 fatty acids vs placebo | Matsuoka et al. 2015 (RCT) SF-36 Mental Component Summary score at 3 months  
  \* MD = -3.00 (95% CI, -7.40 to 1.40; P = 0.18)  
  MD < 0 favours omega-3 fatty acids |
|                                 | Paroxetine vs placebo | Borelli et al. 2019 (RCT) Mean change in SF-36 scores from baseline to 12 months  
  \* Paroxetine: 18.4  
  \* Placebo: 5.0  
  \* P-value for difference was not significant |

CES-D = Center for Epidemiologic Studies Depression Scale; CI = confidence interval; MADRS = Montgomery-Asberg Depression Rating Scale; MD = mean difference; PTSD = post-traumatic stress disorder; QIDS-SR = Quick Inventory of Depressive Symptomatology; RCT = randomized controlled trial; SF-36 = 36-Item Short-Form Health Survey; SR = systematic review.
Appendix 5: Overlap Between Included Systematic Reviews

Note that this appendix has not been copy-edited.

Table 10: Overlap in Relevant Primary Studies Between Included Systematic Reviews

<table>
<thead>
<tr>
<th>Primary study citation</th>
<th>Bertolini et al. (2022)</th>
<th>Astill Wright et al. (2021)</th>
<th>Metcalf et al. (2020)</th>
<th>Merz et al. (2019)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wood NE, et al. Psychiatry Res. 2015;225: 31-39.</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Corchs F, et al. Biol Psychiatry. 2018;83: S129eS455.</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Primary study citation</td>
<td>Bertolini et al. (2022)</td>
<td>Astill Wright et al. (2021)</td>
<td>Metcalf et al. (2020)</td>
<td>Merz et al. (2019)</td>
</tr>
<tr>
<td>-------------------------------------------------------------</td>
<td>-------------------------</td>
<td>-----------------------------</td>
<td>----------------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>Gray R and Bourke F. J Milit Vet Family Health. 2015;1: 13-20.</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Gray RM, et al. Psychol Trauma. 2021;13(6): 641-651.</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>van Zuiden M, et al. Biol Psychiatry. 2017;81: 1030-40</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Freedman SA, et al. Eur J Psychotraumatol. 2020;11: 1750170</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Horsch A, et al. Behav Res Ther. 2017;94: 36-47.</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Iyadurai L, et al. Mol Psychiatry. 2018;18: 674-82.</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Kanstrup MS, et al. Transl Psychiatry. 2021;11: 30</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Rothbaum BO, et al. J Trauma Stress. 2006;19(5): 625-638.</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Rauch SAM, et al. JAMA Psychiatry. 2018;76(2): 117-126.</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Primary study citation</td>
<td>Bertolini et al. (2022)²²</td>
<td>Astill Wright et al. (2021)²³</td>
<td>Metcalf et al. (2020)²⁷</td>
<td>Merz et al. (2019)²⁴</td>
</tr>
<tr>
<td>-----------------------------------------------------------</td>
<td>---------------------------</td>
<td>-------------------------------</td>
<td>------------------------</td>
<td>---------------------</td>
</tr>
<tr>
<td>Litz BT, et al. J Psychiatr Res. 2012;46(9): 1184-1190.</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Yehuda R, et al. Psychoneuroendocrinology. 2015;51: 589-597.</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Fryml LD, et al. J ECT. 2019; 35(1): 53-60.</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Note: Yes indicates the primary study was included within the systematic review; No indicates the primary study was not included within the systematic review.
Appendix 6: References of Potential Interest

Note that this appendix has not been copy-edited.

Previous CADTH Reports

Review Articles
Feduccia AA, Mithoefer MC. MDMA-assisted psychotherapy for PTSD: are memory reconsolidation and fear extinction underlying mechanisms? Prog Neuropsychopharmacol Biol Psychiatry. 2018;84(Pt A):221-228. PubMed

Randomized Controlled Trials